Psyence BioMed Schedules U.S. Outreach on GMP Ibogaine Manufacturing from African Facility
Psyence BioMed’s CEO Jody Aufrichtig will travel to the U.S. to meet researchers, institutions, industry leaders and government stakeholders on regulatory pathways for GMP-compliant ibogaine production. The company’s investment in a Southern Africa PsyLabs facility provides cultivation, extraction, purification and manufacturing capabilities to supply pharmaceutical-grade ibogaine for clinical research.
1. U.S. Strategic Engagement Initiative
Psyence BioMed’s executive leadership, led by CEO Jody Aufrichtig, will travel to the United States in coming weeks to engage researchers, institutions, industry leaders and government stakeholders in discussions on advancing regulatory review pathways and clinical investigation for ibogaine.
2. GMP-Compliant Manufacturing Capabilities
Through its strategic investment in PsyLabs, the company operates a GMP-compliant facility in Southern Africa focused on cultivation, extraction, purification and manufacturing of pharmaceutical-grade ibogaine suitable for regulated clinical trials.
3. Vertically Integrated Supply Chain Positioning
Psyence BioMed’s vertically integrated model covers ethical sourcing, quality control, analytical testing and scalable supply chain management, with existing GMP inventory positioning it among a limited number of organizations capable of meeting future global research demand for ibogaine.